Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial

Olivier Sanchez1,2,3,4 Anaïs Charles-Nelson5,6 Walter Ageno7 Stefano Barco8,9† Harald Binder10

Gilles Chatellier3,5,6 Daniel Duerschmied11 Klaus Empen12 Melanie Ferreira13 Philippe Girard4,14

Menno V. Huisman15 David Jiménez16 Sandrine Katsahian3,5,6,17 Matija Kozak18

Mareike Lankeit8,19,20 Nicolas Meneveau4,21,22 Piotr Pruszczyk23 Antoniu Petris24 Marc Righini25

Stephan Rosenkranz26 Sebastian Schellong27 Branislav Stefanovic28 Peter Verhamme29

Kerstin de Wit30 Eric Vicaute31 Andreas Zirlik32 Stavros V. Konstantinides8,33 Guy Meyer1,3,4,†

1 AP-HP, hôpital européen Georges-Pompidou, Service de Pneumologie et de Soins Intensifs, APHP.Centre - Université de Paris, Paris, France
2 INSERM UMR S 1140 Innovative Therapies in Hemostasis, Paris, France
3 Université de Paris, Paris, France
4 FCRIN INNOVTE, Paris, France
5 AP-HP, hôpital européen Georges-Pompidou, Unité de Recherche Clinique, APHP.Centre, Paris, France
6 INSERM, Centre d’Investigation Clinique 1418 (CIC1418) Épidémiologie Clinique, Paris, France
7 Department of Medicine and Surgery, University of Insubria, Varese, Italy
8 Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany
9 Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland
10 Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
11 Department of Cardiology and Angiology I, University Heart Center Freiburg - Bad Krozingen, Faculty of Medicine, University of Freiburg, Freiburg, Germany
12 Department of Internal Medicine, Städtisches Klinikum Dessau, Germany
13 Internal Medicine Department, Hospital Garcia de Orta, Almada, Portugal
14 Département Thoracique, Institut Mutualiste Montsouris, Paris, France

Address for correspondence Stavros V. Konstantinides, MD, Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Building 403, 55131 Mainz, Germany (e-mail: stavros.konstantinides@unimedizin-mainz.de).

15 Department of Thrombosis and Hemostasis, Leiden University Medical Center, Dutch Thrombosis Network, Leiden, The Netherlands
16 Department of Respiratory Diseases, Ramon y Cajal Hospital, Universidade de Alcalá (IRYCIS), CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
17 INSERM UMR_S 1138 équipe 22, Centre de Recherche des Cordeliers, Paris, France
18 Institute for Vascular Medicine, University Medical Center, Ljubljana, Slovenia
19 Department of Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany
20 Clinic of Cardiology and Pneumology, University Medical Center Goettingen, Goettingen, Germany
21 Department of Cardiology, University Hospital Jean Minjoz, Besançon, France
22 EA3920, Université de Bourgogne Franche-Comté, Besançon, France
23 Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland
24 Grigore T. Popa University of Medicine and Pharmacy Iasi, Cardiology Clinic, “St. Spiridon” County Clinical Emergency Hospital, Iasi, Romania

© 2021. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
Background and Rationale

Advanced Risk Stratification of Pulmonary Embolism

Assessment of the clinical severity of acute pulmonary embolism (PE) is based on the estimated risk of early (in-hospital or 30-day) mortality. High-risk PE, defined by the presence of hemodynamic instability at presentation, is a life-threatening condition in which prompt reperfusion treatment is needed to increase the chances of survival. However, the vast majority of patients with acute PE do not present with overt hemodynamic compromise. Within this large, apparently stable group, prediction scores derived from clinical variables permit further risk stratification. For example, a Pulmonary Embolism Severity Index (PESI) risk class of I or II, a simplified PESI (SPESI) of 0, or the absence of Hestia criteria all have a high negative predictive value for ruling out an early adverse outcome (low-risk PE). On the other hand, hemodynamically stable patients who do not fulfill these criteria belong to the intermediate-risk category. Numerous studies could show that, in intermediate-risk PE, imaging parameters and laboratory biomarkers possess additive prognostic value, complementing each other as well as baseline clinical parameters. Accordingly, patients are classified into the intermediate–high-risk category if they have evidence of right ventricular (RV) dysfunction on echocardiography or computed tomography pulmonary angiography, in combination with elevated plasma cardiac troponin levels.
Unfavorable Risk-to-benefit Profile of Full-Dose Systemic Thrombolysis

The superior hemodynamic effects and faster onset of action (compared with heparin anticoagulation alone) of systemic thrombolytic (fibrinolytic) treatment have been established, and its use is recommended in the emergency setting of acute high-risk PE. However, it has remained controversial for decades whether systemic thrombolysis might also improve the clinical outcome of hemodynamically stable patients, particularly those with intermediate–high-risk PE. Following first promising data in the early 2000s, the Pulmonary Embolism International Thrombolysis (PEITHO) trial confirmed the clinical efficacy of full-dose thrombolysis (using tenecteplase) in this risk group. That study showed a significant reduction (odds ratio [OR]: 0.44; 95% confidence interval [CI]: 0.23–0.87) in the clinical composite of death from any cause or hemodynamic collapse within 7 days after randomization. However, this benefit came at a high price: in PEITHO, stroke occurred in 12 patients (2.4%) randomized to the thrombolysis arm (OR: 12.10; 95% CI: 1.57–93.39 vs. heparin alone), being hemorrhagic in 10 cases. Considering the high risk of intracranial or other life-threatening bleeding events, which was subsequently confirmed by meta-analyses, current guidelines do not recommend systemic thrombolysis as first-line treatment in intermediate–high-risk PE. Lastly, the PEITHO trial had not been designed to answer the question whether early systemic thrombolysis may prevent the development of late sequelae thromboembolic pulmonary hypertension (chronic thromboembolic pulmonary hypertension) after intermediate-risk PE.

Reduced-Dose Thrombolysis Might Improve Safety While Maintaining Efficacy

In patients with acute PE, three small randomized trials compared a reduced dose of alteplase with the conventional 100 mg regimen (received by a total of 162 and 99 patients, respectively, in the pooled study population). The reduced-dosage regimens varied amongst the studies: in one of them, 50 mg of alteplase was infused over 2 hours, whereas in the two other studies, a weight-adapted dose of 0.6 mg/kg, up to a total of 50 mg, was given over 15 minutes. There were no significant differences in efficacy between the reduced-dose and the standard-dose regimen, as judged by changes in pulmonary artery pressure, cardiac index or residual vascular obstruction at 24 hours, or the incidence of PE recurrence. In addition, and importantly, a meta-analysis suggested that a reduced dosage may be associated with reduction in the risk of major bleeding (OR: 0.33; 95% CI: 0.12–0.91).

The efficacy of the reduced-dose regimen is further supported by two studies comparing alteplase, at the dose of 0.6 mg/kg or 0.5 mg/kg (maximum of 50 mg), with heparin alone in patients with acute PE. A greater improvement of vascular obstruction was observed with alteplase in the former study, whereas the latter reported a reduction in the combined endpoint of persistent pulmonary hypertension or recurrent PE over the long term.

Taken together, reperfusion treatment employing systemic thrombolysis exerts favorable hemodynamic effects, and thrombolytic regimens may be capable of improving the prognosis of patients with acute intermediate–high-risk PE. Nevertheless, the bleeding risk of full-dose intravenous thrombolysis is too high to justify its use as first-line therapy in this risk category. Today, reduced-dose regimens are becoming increasingly popular in clinical practice worldwide, despite the explicit warning by scientific societies and guidelines that the available evidence is not (yet) sufficient to support their efficacy and safety. This potentially dangerous gap in knowledge must therefore be closed as soon as possible. An adequately powered randomized placebo-controlled clinical trial, focusing on clinically relevant efficacy and safety outcomes, is the only way to determine the benefits versus risks of reduced-dose thrombolysis in acute PE.

Study Overview

Study Design and Objectives

The Pulmonary Embolism International Trial (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. The primary objective is to assess the efficacy (defined as the ability to prevent death, hemodynamic decompensation, or PE recurrence) of reduced-dose intravenous thrombolytic therapy with alteplase, against the background of standard care (heparin anticoagulation), in patients with acute intermediate–high-risk PE, 30 days after randomization. The secondary objectives are to assess (1) the safety, net clinical benefit, and impact of reduced-dose thrombolytic therapy on overall mortality in patients with intermediate–high-risk PE, as well as (2) the effect on long-term mortality, functional impairment, residual RV dysfunction, and the incidence of chronic thromboembolic pulmonary hypertension.

Patient Population and Eligibility

The key inclusion and exclusion criteria are summarized in Table 1. In this context, it is important to explain the rationale for the advanced definition of intermediate–high-risk PE used in the present study. In fact, both past and current guidelines defined intermediate–high-risk PE based “exclusively” on imaging (evidence of RV dysfunction) and biochemical (circulating levels of elevated laboratory biomarkers) criteria. Although these modalities generally possess high sensitivity, validated in several cohort studies and a randomized trial (reviewed in Konstantinides et al), their prognostic specificity as standalone tools may be too low to predict threatening cardiorespiratory decompensation. They may thus not suffice to identify the patients closer to the “upper border” of the intermediate-risk zone, who are expected to obtain the largest possible clinical benefit from early thrombolytic treatment. To address this limitation, we sought to identify additional baseline predictors of early life-threatening events in the population of a large PEITHO trial, in which overall early mortality was low. We found that initial systolic blood pressure ≤ 110 mm Hg, respiratory...
Table 1  Key inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Age 18 years or older</td>
<td>1. High-risk PE with hemodynamic instability(^1)</td>
</tr>
<tr>
<td>2. Objectively confirmed acute PE with first symptoms (\leq 2) weeks before randomization, (\geq 1) of the following criteria required:</td>
<td>2. Active bleeding</td>
</tr>
<tr>
<td>a. (\geq 1) segmental ventilation-perfusion mismatch on lung scan</td>
<td>3. History of nontraumatic intracranial bleeding</td>
</tr>
<tr>
<td>b. CTPA/pulmonary angiography showing filling defect or abrupt obstruction of a segmental/more proximal pulmonary artery</td>
<td>4. Acute ischemic stroke or transient ischemic attack in the past 6 months</td>
</tr>
<tr>
<td>3. Elevated risk of early death or hemodynamic collapse, indicated by (\geq 1) of the following criteria:</td>
<td>5. Neurosurgery or eye surgery; abdominal, cardiac, thoracic, or vascular surgery; or orthopaedic surgery or trauma, in the past 3 weeks</td>
</tr>
<tr>
<td>a. SBP (\leq 110) mm Hg over (\geq 15) minutes</td>
<td>6. Known central nervous system neoplasm or metastasis</td>
</tr>
<tr>
<td>b. Temporary need for fluid resuscitation and/or treatment with low-dose catecholamines because of arterial hypotension at presentation, provided that the patient could be stabilized within (2) hours of admission and maintains SBP of (\geq 90) mm Hg and adequate organ perfusion without catecholamine infusion</td>
<td>7. Platelet count (&lt; 100 \times 10^9/L)</td>
</tr>
<tr>
<td>c. Respiratory rate (&gt; 20) per minute or oxygen saturation on pulse oximetry (Sp(\text{O}_2)) (&lt; 90%) or partial arterial oxygen pressure (&lt; 60) mm Hg at rest while breathing room air</td>
<td>8. INR (&gt; 1.4)</td>
</tr>
<tr>
<td>d. History of chronic heart failure, defined as previous diagnosis of heart failure with reduced, moderately reduced, or preserved ejection fraction, or treatment for heart failure at any time during the past 12 months</td>
<td>9. Administration of thrombolytic agents in the preceding 4 days</td>
</tr>
<tr>
<td>4. RV dysfunction, indicated by RV/LV diameter ratio (&gt; 1.0) on echocardiography (apical four-chamber or subcostal four-chamber view) or on CTPA (transverse plane)</td>
<td>10. Antiplatelet agents other than ASA (\leq 100) mg once daily; clopidogrel 75 mg once daily or a single loading dose of ASA or clopidogrel</td>
</tr>
<tr>
<td>5. Serum troponin I or T concentration above the upper limit of local normal using a high-sensitive assay</td>
<td>11. Any direct oral anticoagulant within (12) hours of randomization</td>
</tr>
<tr>
<td>6. Signed informed consent</td>
<td>12. Known significant bleeding risk according to investigator’s judgment</td>
</tr>
</tbody>
</table>

Note: Patients who test positive for SARS-CoV-2 may be randomized, if the investigator judges that the acute PE (and not the infection with SARS-CoV-2) is responsible for the patient’s clinical, imaging, and hemodynamic parameters meeting the trial’s inclusion criteria.

Abbreviations: ASA, acetylsalicylic acid; CTPA, computed tomography pulmonary angiography; INR, international normalized ratio; LV, left ventricular; PE, pulmonary embolism; RV, right ventricular; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SBP, systolic blood pressure.

rate \(> 20\) breaths/min (or, as a surrogate, an arterial oxygen saturation \(< 90\%\) on room air) at presentation, or a history of chronic heart failure, predicted, alone or in combination, death from any cause, hemodynamic decompensation, or objectively confirmed recurrent PE within \(30\) days of randomization. The presence of at least one of these criteria thus defined an enriched patient population (53\% of the patients enrolled in that study), in which the incidence of the composite clinical outcome was 11.2\% in the control group as opposed to as low as 3.7\% in the thrombolysis group.\(^{25}\) This group was defined as the target population in the present trial, with the aim to obtain an optimized benefit-to-risk ratio from early thrombolysis.

Treatment Regimens

The diagram shown in ►Fig. 1 depicts the study flow and the allowed time intervals between consecutive trial procedures and visits. An overview of the tests to be performed and parameters to be collected upon enrolment and at the follow-up visits is provided in ►Table 2. Patients fulfilling all the inclusion criteria and none of the exclusion criteria (►Table 1) will be randomized into the experimental or the reference treatment arm. Patients will receive alteplase (if randomized into the experimental arm) or placebo (if randomized into the reference arm), to be given within \(30\) minutes of randomization. Patients will receive alteplase (if randomized into the experimental arm) or placebo (if randomized into the reference arm), to be given within \(30\) minutes of randomization. The patient at increased risk upon start of the investigational treatment may be stabilized within \(2\) hours of admission and maintains SBP of \(\geq 90\) mm Hg and adequate organ perfusion without catecholamine infusion.

Both treatment arms will receive anticoagulant treatment using low-molecular-weight heparin (LMWH) or any other type of heparin approved for the treatment of acute PE, according to local practice. If anticoagulation has been initiated using unfractionated heparin (UFH) and a switch to LMWH is envisaged after randomization, the UFH infusion will be stopped at the time of randomization and the first LMWH subcutaneous injection will be given within \(3\) hours.
Fig. 1 Overview of design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. AEs, adverse events; PE, pulmonary embolism; RV, right ventricular; i.v., intravenously; V, visit.

Table 2 Trial visit plan and data collection schedule

<table>
<thead>
<tr>
<th>Verification of inclusion and exclusion criteria</th>
<th>In hospital</th>
<th>Outpatient follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Signed informed consent</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Medical interview</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>- Demographics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Medical history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Concomitant antiplatelet and anticoagulant treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical examination</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Troponin I and/or t-test</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Further laboratory tests</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>RV/LV diastolic diameter ratio</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>sPESI</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Study drug administration</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pregnancy test</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>(for women of childbearing age)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Documentation of (serious) adverse events</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Utilization of health care resources</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Abbreviations: LV, left ventricular; RV, right ventricular; sPESI, simplified Pulmonary Embolism Severity Index.

*Including body weight, blood pressure, heart rate, arterial oxygen saturation, respiratory rate, clinical signs of right heart failure.

*Creatinine, international normalized ratio, hemoglobin (1 day after randomization), platelet count (before and after randomization).

*Patients will be continuously monitored for early detection of hemodynamic instability or major bleeding.
of the end of UFH infusion. If anticoagulation has been initiated with LMWH as a twice-daily regimen, the next LMWH injection will be given 12 hours after the previous one. If fondaparinux, or LMWH as once-daily injection, has been given before randomization, the next injection will be given 24 hours after the previous one. Due to the longer half-life of fondaparinux as compared with LMWH, a switch from that drug to LMWH (or UFH) is generally recommended over the first 48 hours. The use of direct oral anticoagulants (apixaban, betrixaban, dabigatran, edoxaban, rivaroxaban) and vitamin K antagonists will not be allowed within the first 48 hours after randomization. All approved anticoagulant regimens will be allowed 48 hours after randomization. As recommended by current guidelines, all patients will receive therapeutic anticoagulation for at least 3 months. After the first 3 months, discontinuation or extension of the anticoagulant treatment will be at the discretion of the treating physician.

Outcomes
The efficacy and safety outcomes of the PEITHO-3 trial are summarized in Table 3. The primary efficacy outcome is the clinical composite of death from any cause, hemodynamic decompensation, or objectively confirmed recurrent PE within 30 days of randomization. When defining the primary efficacy outcome, we took into account that early mortality is relatively low in patients with intermediate-risk PE receiving contemporary, state-of-the-art supportive care such as that provided in the setting of a randomized controlled trial. Thus, the sample size required for a trial aiming to show a “pure mortality benefit” from thrombolysis would be prohibitively large. On the other hand, other relevant adverse outcomes, notably early hemodynamic collapse or decompensation, are more frequent in patients with intermediate–high-risk PE treated with anticoagulation, and they represent a valid component of overall clinical efficacy. In addition, by including all-cause (and not only PE-related) mortality in the composite primary outcome, we aim to ensure that, if superiority of reduced-dose thrombolysis over heparin alone is shown in the present study, it will have accounted for any thrombolysis-related fatal bleeding events. In the same context, the GUSTO definition of bleeding was chosen because it directly reflects the possible impact of bleeding complications on death or hemodynamic compromise/decompensation. Consequently, possible opposing effects of reduced-dose thrombolysis on efficacy and safety (such as prevention of PE-related death or decompensation at the cost of excessive fatal bleeding or hemorrhage-induced hemodynamic compromise) will both be taken into account in the primary clinical outcome. PEITHO-3 thus aims to provide a clear message to physicians regarding the overall clinical benefit of thrombolysis in patients with intermediate–high-risk PE rigorously defined by clinical, imaging, and biochemical criteria.

All primary and secondary outcomes will be adjudicated by an independent clinical events committee.

Sample Size Calculation and Statistical Analysis Plan
To calculate the sample size for the present study, we performed a post hoc analysis of the population of the PEITHO trial, the largest (full-dose) thrombolysis trial with

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Primary and secondary outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td>Clinical composite of death from any cause or hemodynamic decompensation or objectively confirmed recurrent PE within 30 days of randomization</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>To be included in a hierarchical analysis:</td>
</tr>
<tr>
<td></td>
<td>1. Fatal or GUSTO severe or life-threatening bleeding, defined as either intracranial bleeding or bleeding leading to significant hemodynamic compromise requiring treatment, within 30 days</td>
</tr>
<tr>
<td></td>
<td>2. Net clinical benefit, defined as the composite of the primary efficacy outcome and GUSTO severe or life-threatening bleeding, within 30 days</td>
</tr>
<tr>
<td></td>
<td>3. All-cause mortality within 30 days</td>
</tr>
<tr>
<td></td>
<td>Not to be included in the hierarchical analysis:</td>
</tr>
<tr>
<td></td>
<td>4. PE-related death within 30 days of randomization</td>
</tr>
<tr>
<td></td>
<td>5. Hemodynamic decompensation within 30 days</td>
</tr>
<tr>
<td></td>
<td>6. Recurrent PE within 30 days</td>
</tr>
<tr>
<td></td>
<td>7. Need for rescue thrombolysis, catheter-directed treatment, or surgical embolectomy within 30 days</td>
</tr>
<tr>
<td></td>
<td>8. Ischemic or hemorrhagic stroke within 30 days</td>
</tr>
<tr>
<td></td>
<td>9. Serious adverse events within 30 days</td>
</tr>
<tr>
<td></td>
<td>10. Utilization of health care resources within 30 days and 6 months</td>
</tr>
<tr>
<td></td>
<td>11. All-cause mortality at 2 years</td>
</tr>
<tr>
<td></td>
<td>12. Persisting dyspnea assessed by the Medical Research Council (MRC) scale at 6 months and at 2 years</td>
</tr>
<tr>
<td></td>
<td>13. Functional outcome, using the post-VTE functional scale, at 6 months and at 2 years</td>
</tr>
<tr>
<td></td>
<td>14. Persistent RV dysfunction, defined as an intermediate or high probability of pulmonary hypertension on echocardiography according to ESC criteria, at 6 months and 2 years</td>
</tr>
<tr>
<td></td>
<td>15. Confirmed chronic thromboembolic pulmonary hypertension according to ESC criteria at 2 years</td>
</tr>
</tbody>
</table>

Abbreviations: ESC, European Society of Cardiology; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; PE, pulmonary embolism; RV, right ventricular; VTE, venous thromboembolism.
clinical outcomes conducted to this date.²⁵ This analysis helped to estimate the incidence of the primary efficacy outcome (death from any cause or hemodynamic collapse or objectively confirmed recurrent PE within 30 days of randomization) as defined in the present study, PEITHO-3. More specifically, in the subgroup of patients included in PEITHO, who would have fulfilled the “enriched” inclusion criteria of the present study, the rates were 11.2 and 3.7% in the control and (standard-dose) thrombolysis groups, respectively (relative risk reduction 67%). For estimating efficacy in PEITHO-3, we conservatively assumed a 55% relative risk reduction, corresponding to a 5.0% expected incidence in the reduced-dose thrombolysis group. Taking into account a planned interim analysis (see below) with the Lan and DeMets methods, we calculated that several \((n = 305)\) patients per treatment arm will allow a 80% power to show the expected relative risk reduction. The nominal \(\alpha\) at final analysis will be set at 0.049 for the primary analysis according to the Lan–DeMets²⁶ monitoring boundary with an O’Brien–Fleming stopping rule, provided that no sample size modification will be needed; otherwise, the final significance level will be adjusted accordingly.²⁷ Accounting for possible early drop-outs, it is planned to enroll and randomize a total of 650 patients; the final size of the trial population will depend on the results of the interim analysis as explained below.

The primary analysis on the primary outcome will be performed in the ITT population applying a logistic regression analysis to account for stratification factors²⁸,²⁹; the group variables age (>75 vs. ≤75 years) and country will be included in the model. Results will be presented as OR and associated 95% CI. In addition, two exploratory subgroup analyses will be performed for the primary outcome in the ITT population, according to the following variables: (1) >75 versus ≤75 years, and (2) presence of >2 clinical criteria of PE severity at presentation (among the following inclusion criteria: systolic blood pressure ≤110 mm Hg; respiratory rate >20/min or, as a surrogate, arterial oxygen saturation <90% on room air; history of chronic heart failure) versus one criterion. An interaction term between subgroup variable and the treatment variable will be included in the logistic model, to assess whether the interaction is significantly associated to the primary outcome. Results will be presented as a forest plot.

In addition to improving early clinical outcomes, utilization of health care resources will be recorded for each patient at two time points (30 days and 180 days) postrandomization. For outpatient visits and periods of hospitalization, country-specific standardized unit costs will be applied, representing costs from a societal perspective. In addition, PE-related resource utilization will be recorded.

Safety Monitoring, Interim Analysis, and Stopping Rules

An independent data and safety monitoring board (DSMB) will be assessing the safety of the study. The DSMB will periodically review the serious adverse events (SAEs) with a special attention to the major bleeding events and will communicate its recommendations to the sponsor about stopping or continuing the trial. As specified in a dedicated charter, the frequency of DSMB meetings will be scheduled every 20 SAEs. Additional meetings may be arranged, especially if the SAE numbers are higher than anticipated. An independent statistician will conduct a formal efficacy interim analysis and sample size re-estimation based on the adjudicated primary efficacy outcome of 50% of the expected total number of patients. The superiority of the experimental treatment versus the control arm will be assessed by the chi-square test. To provide an overall two-sided significance level close to 0.05 for the study, the interim analysis will have a Lan–DeMets monitoring boundary with an O’Brien–Fleming stopping rule.²⁶ The study will stop for efficacy if the \(p\)-value provided by the chi-square test is <0.003. The study will stop for futility if the conditional probability (based on the observed treatment effect) of rejecting the null hypothesis is <0.5.

Implications of PEITHO-3

It has been almost 18 years since the first PEITHO trial was launched. The PEITHO investigators set out to resolve a longstanding controversy concerning the efficacy versus safety of reperfusion treatment for patients with acute PE presenting with findings of acute RV pressure overload and dysfunction despite apparently normal systemic blood pressures.³⁰,³¹ PEITHO helped to advance the definition of intermediate-risk PE, and it showed that patients belonging to the intermediate–high-risk class may clinically benefit from systemic thrombolysis as first-line treatment. However, that trial also showed that the bleeding risks of full-dose intravenous thrombolysis predominate over its clinical and hemodynamic effects.¹⁴ In view of these results, the focus of the debate has shifted toward identifying safer reperfusion modalities. Percutaneous catheter-directed treatment of acute PE, aiming a mechanical thrombus removal with or without local thrombolysis, has shown promising effects on surrogate imaging or hemodynamic parameters.³²–³⁵ However, for the majority of countries and hospitals around the world, intravenous thrombolysis is expected to remain a more affordable and more feasible option in terms of required expertise, infrastructure, and resources. The present randomized controlled trial will address a large unmet need by testing the hypothesis that reduced-dose systemic thrombolysis may improve the prognosis of patients with acute intermediate–high-risk PE at an acceptably low risk of major bleeding complications. In this context it is further anticipated, as also suggested by the results of meta-analyses,¹⁵,³⁶ that the use of alteplase in the present trial will be associated with a lower risk of intracranial hemorrhage and other major bleeding compared with tenecteplase used in PEITHO.¹⁴ If the hypothesis of PEITHO-3 is confirmed, international clinical practice guidelines will most likely revisit their recommendations by including reperfusion and particularly reduced-dose systemic thrombolysis as first-line treatment in this risk class. If the hypothesis is rejected, catheter-directed treatment may become the only option for improving the prognosis of patients with intermediate–high-risk PE,³⁷ provided that it can demonstrate clinical efficacy and
safety in future state-of-the-art randomized controlled trials. In any case, the results of the present trial are expected to have a major impact on future risk-adjusted treatment strategies for patients with acute PE.

**Study Committees and Investigators**

**Scientific Steering Committee**
Olivier Sanchez, Paris, France; Stavros Konstantinides, Mainz, Germany; Walter Ageno, Varese, Italy; Melanie Ferreira, Almada, Portugal; Menno V. Huisman, Leiden, The Netherlands; David Jiménez, Madrid, Spain; Sandrine Katsahian, Paris, France; Matija Kozak, Ljubljana, Slovenia; Mareike Lankeit, Berlin, Germany; Nicolas Meneveau, Besançon, France; Piotr Pruszczynk, Warsaw, Poland; Antoniu Petris, Iasi, Romania; Marc Righini, Geneva, Switzerland; Branislav Stefanovic, Serbia; Peter Verhamme, Leuven, Belgium; Kerstin de Wit, Hamilton, Ontario, Canada; Andreas Zirlik, Graz, Austria.

**Executive Committee**
Olivier Sanchez, Paris, France; Stavros Konstantinides, Mainz, Germany; Yvann Frigout, Paris, France; Aurélie Guimfack, Paris, France; Dorothea Becker, Mainz, Germany; Nadine Martin, Mainz, Germany; Louise Goedhart (Aixial, Boulogne-Billancourt, France; contract research organization).

**Trial Statisticians**
Anaïs Charles-Nelson, Sandrine Katsahian, Eric Vicaut, Paris, France; Harald Binder, Freiburg, Germany.

**Data Safety Monitoring Board**
Jean-Philippe Collet, Paris, France; Drahomir Aujesky, Bern, Switzerland; Silvy Laporte, Saint Etienne, France.

**Clinical Events Adjudication Committee**
Joseph Emmerich, Paris, France; Cécile Tromeur, Brest, France; Stefano Barco, Zurich, Switzerland.

**Funding**
The work of Stavros Konstantinides was supported by the German Federal Ministry of Education and Research (BMBF 01EO1003 and 01EO1503). The authors are responsible for the contents of this publication.

PEITHO-3 is an independent, investigator-initiated trial. The study is being supported by public funding, specifically by grants from the French Ministry of Health (PHRCN-16–0580), the German Research Foundation (Deutsche Forschungsgemeinschaft; KO 1939/3–1), the Canadian Institutes of Health Research and the Spanish Ministry of Science and Innovation. In addition, the sponsor, Assistance Publique – Hôpitaux de Paris, has obtained the study drug and a grant from the market authorization holder of alteplase, Boehringer Ingelheim. The authors are solely responsible for the design and conduct of the trial, for all study analyses, and for the drafting and editing of reports and publications and their final contents.

**Conflict of Interest**

O.S. has received institutional research grants from Bayer, Leo Pharma, Bristol-Myers Squibb, Merck Sharp and Dome, Daiichi-Sankyo, Boehringer Ingelheim, and Sanofi; and personal consultancy/speaker fees from Bayer, Bristol-Myers Squibb, Pfizer, Boston Scientific, Merck Sharp and Dome, Boehringer Ingelheim, Sanofi, and Chiesi. S.B. has received congress and travel payments from Daiichi-Sankyo and Bayer AG, honoraria from BTG Pharmaceuticals, Boston Scientific, Bayer HealthCare, and Leo Pharma, and institutional grants from Sanofi, outside the submitted work. W.A. reports research support from Bayer; activity in advisory boards for Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola, Janssen, Aspen, and Sanofi. D.D. has received speaker’s honoraria from Bayer Vital, Daiichi-Sankyo, and Pfizer/Bristol-Myers Squibb, and consulting fees from Bayer Vital and Daiichi-Sankyo. In addition, D.D. is a member of SFB1425, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation #422681845). K.E. reports lecture fees from AstraZeneca, Bayer Vital, Berlin Chemie, Boehringer Ingelheim, and Novartis, and consulting fees from Bayer Vital, Boehringer Ingelheim, Novartis, and Novo Nordisk. M.F. reports lecture fees and travel grants from Bayer, Bristol-Myers Squibb, and Pfizer, and travel grants from Daiichi-Sankyo and Leo Pharma. M.V.H. reports grants from ZonMW Dutch Healthcare Fund, and grants and personal fees to the hospital from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Bayer Health Care, Aspen, and Daiichi-Sankyo, all outside the submitted work. D.J. has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; served as a speaker or a member of a speakers’ bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; received grants for clinical research from Daiichi-Sankyo and Leo Pharma. M.V.H. has received speaker and travel grants from Bayer, Bristol-Myers Squibb, and Pfizer, and travel grants from Daiichi-Sankyo and Leo Pharma. M.V.H. has received institutional research grants from Bayer, Leo Pharma, Bristol-Myers Squibb, Merck Sharp and Dome, Daiichi-Sankyo, Boehringer Ingelheim, and Sanofi; and personal consultancy/speaker fees from Bayer, Bristol-Myers Squibb, Pfizer, Boston Scientific, Merck Sharp and Dome, Boehringer Ingelheim, Sanofi, and Chiesi. S.B. has received congress and travel payments from Daiichi-Sankyo and Bayer AG, honoraria from BTG Pharmaceuticals, Boston Scientific, Bayer HealthCare, and Leo Pharma, and institutional grants from Sanofi, outside the submitted work. W.A. reports research support from Bayer; activity in advisory boards for Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola, Janssen, Aspen, and Sanofi. D.D. has received speaker’s honoraria from Bayer Vital, Daiichi-Sankyo, and Pfizer/Bristol-Myers Squibb, and consulting fees from Bayer Vital and Daiichi-Sankyo. In addition, D.D. is a member of SFB1425, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation #422681845). K.E. reports lecture fees from AstraZeneca, Bayer Vital, Berlin Chemie, Boehringer Ingelheim, and Novartis, and consulting fees from Bayer Vital, Boehringer Ingelheim, Novartis, and Novo Nordisk. M.F. reports lecture fees and travel grants from Bayer, Bristol-Myers Squibb, and Pfizer, and travel grants from Daiichi-Sankyo and Leo Pharma. M.V.H. reports grants from ZonMW Dutch Healthcare Fund, and grants and personal fees to the hospital from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Bayer Health Care, Aspen, and Daiichi-Sankyo, all outside the submitted work. D.J. has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; served as a speaker or a member of a speakers’ bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; received grants for clinical research from Daiichi-Sankyo, Sanofi, and ROVI. M.K. reports speaker fees from Pfizer, Boehringer Ingelheim, and Bayer AG, outside the submitted work. M.L. reports consultant and speaker fees from Aspen, Pfizer, Boehringer Ingelheim, and Bayer AG, outside the submitted work. M.L. reports consultant and speaker fees from Actelion, Bayer, Thermo Fisher Scientific, Daiichi-Sankyo, MSD, and Bristol-Myers Squibb-Pfizer, and project funding from Thermo Fisher Scientific. N.M. reports consulting fees, speaker fees, and project funding from Bayer AG and Bristol-Myers Squibb/Pfizer; speaker fees from AstraZeneca and Boehringer Ingelheim; and consulting fees from Abbott and Terumo. A.P. reports speaker fees from S.C. Pfizer Romania SRL, Servier Pharma SRL, Novartis Pharma Services Romania SRL, Bayer SRL, and SC Sanience SRL. S.R. received honoraria for lectures and/or consultancy from Abbott, Acceleron, Actelion, Arena, Bayer, BMS, Ferrer, Janssen, MSD, Novartis, Pfizer, United Therapeutics, and Vifor, and institutional research grants from Actelion, AstraZeneca, Bayer, Janssen, and Novartis. S.S. has received consulting fees and speaker fees from Aspen and Boehringer Ingelheim, speaker fees from Bayer AG.
and Daiichi-Sankyo, and project funding and speaker fees from Pfizer/Bristol-Myers Squibb. P.V. received honoraria for lectures and/or consultancy from Anthos Therapeutics, Bayer, Boehringer, Daiichi-Sankyo, BMS, and Pfizer, and research support from Bayer, Daiichi-Sankyo, BMS, and Pfizer. S.K. reports institutional research grants and personal consultancy/speaker fees from Actelion/Janssen, Bayer AG, Daiichi-Sankyo, and Boston Scientific; institutional research grants from Boehringer Ingelheim and Servier; and personal consultancy/speaker fees from Bristol-Myers Squibb/Pfizer and Novartis. All other authors report no conflict of interest.

Acknowledgments

The authors dedicate this manuscript to the memory of Professor Guy Meyer who died in December 2020. Guy Meyer was one of the main inspirers of the PEITHO trials and founders of the PEITHO investigator network; he worked hard on finalizing the PEITHO-3 protocol until the last days of his life. Beyond being a skilled clinician and academic researcher, he was a unique motivator and fostered the career of numerous talented physician-scientists.

References


Thrombosis and Haemostasis © 2021. The Author(s).
29 Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012;345:e5840